Fluorescence in situ hybridization analysis of the ALK gene in 2,045 non-small cell lung cancer patients from North-Western Spain (Galicia)

Sánchez‑Ares,María; Cameselle‑Teijeiro,José  M.; Vázquez‑Estévez,Sergio; Lázaro‑Quintela,Martín; Vázquez‑Boquete,Ángel; Afonso‑Afonso,Francisco J.; Casal‑Rubio,Joaquín; González‑Piñeiro,Ana   L.; Rico‑Rodríguez,Yolanda; Fírvida‑Pérez,José  L.; Ruíz‑Bañobre,Juan; Couso,Elena; Santomé,Lucía; Pérez‑Becerra,Raquel; García‑Campelo,Rosario; Amenedo,Margarita; Azpitarte‑Raposeiras,Cristina; Antúnez,José; Abdulkader,Ihab

doi:10.3892/ol.2016.4788

Fluorescence in situ hybridization analysis of the ALK gene in 2,045 non-small cell lung cancer patients from North-Western Spain (Galicia)

Authors:
- María Sánchez‑Ares
- José M. Cameselle‑Teijeiro
- Sergio Vázquez‑Estévez
- Martín Lázaro‑Quintela
- Ángel Vázquez‑Boquete
- Francisco J. Afonso‑Afonso
- Joaquín Casal‑Rubio
- Ana L. González‑Piñeiro
- Yolanda Rico‑Rodríguez
- José L. Fírvida‑Pérez
- Juan Ruíz‑Bañobre
- Elena Couso
- Lucía Santomé
- Raquel Pérez‑Becerra
- Rosario García‑Campelo
- Margarita Amenedo
- Cristina Azpitarte‑Raposeiras
- José Antúnez
- Ihab Abdulkader
View Affiliations

Affiliations: Department of Anatomic Pathology, Clinical University Hospital, Galician Healthcare Service (SERGAS), 15706 Santiago de Compostela, Spain, Department of Medical Oncology, Lucus Augusti University Hospital, SERGAS, 27003 Lugo, Spain, Department of Medical Oncology, University Hospital Complex, SERGAS, 36312 Vigo, Spain, Department of Medical Oncology, University Hospital Complex Arquitecto Marcide‑Novoa Santos, SERGAS, 15405 Ferrol, Spain, Department of Anatomic Pathology, University Hospital Complex, SERGAS, 36312 Vigo, Spain, Department of Medical Oncology, Clinical University Hospital, SERGAS, 32005 Ourense, Spain, Department of Medical Oncology, Clinical University Hospital, SERGAS, 15706 Santiago de Compostela, Spain, Department of Medical Oncology, Povisa Hospital, 36211 Vigo, Spain, Department of Medical Oncology, Clinical University Hospital, SERGAS, 15006 A Coruña, Spain, Department of Medical Oncology, Centro Oncológico de Galicia, 15009 A Coruña, Spain, Department of Medical Oncology, Clinical University Hospital, SERGAS, 36164 Pontevedra, Spain
Published online on: June 28, 2016 https://doi.org/10.3892/ol.2016.4788
Pages: 1403-1407
Copyright: © Sánchez‑Ares et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Identification of anaplastic lymphoma receptor tyrosine kinase (ALK) gene rearrangements is a standard diagnostic test in patients with advanced non-small cell lung cancer (NSCLC). The current study describes the experience of ALK rearrangement detection of a referral center in the public health care system of Galicia in North‑Western Spain. The fluorescence in situ hybridization (FISH) patterns of the ALK gene and the clinical and pathological features of these patients are reported. This study is also of interest for comparative purposes due to the relative geographical isolation of the area, which could have contributed to particular genetic features. A total of 2,045 tissue samples from NSCLC patients were collected between October 2010 and July 2015 and tested for ALK rearrangements by FISH. Examination of 1,686 paraffin‑embedded tissue specimens and 395 cytological samples (306 cell block preparations and 53 cytological smears) was conducted, and any associations between the FISH results and clinicopathological features were assessed. The rate of successful evaluation was marginally higher in tissue samples than in cytological samples (92.9% vs. 84.1%); this difference was not significant. ALK rearrangements were identified in 82 patients(4%): 65 (79.3%) in tissue specimens, 15 (18.3%) in cell block samples and 2 (2.4%) in cytological smears. This genetic translocation appeared to be associated with a non‑smoking history, younger age, female gender, stage IV and adenocarcinoma histological type. The findings demonstrate that ALK evaluation by FISH is feasible in tissue and cytological samples. The clinical and pathological features of the ALK‑positive series of patients are similar to those previously reported in the literature.

View Figures

View References

1	Travis WD, Brambilla E, Burke AP, Marx A and Nicholson AG: Tumours of the lung. Who Classification Of Tumours Of Lung, Pleura, Thymus And Heart (4th). IARC Press. (Lyon, France). 9–151. 2015.
2	Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 363:1693–1703. 2010. View Article : Google Scholar : PubMed/NCBI
3	Patel JN, Ersek JL and Kim ES: Lung cancer biomarkers, targeted therapies and clinical assays. Transl Lung Cancer Res. 4:503–514. 2015.PubMed/NCBI
4	Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, et al: Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American pathologists, international association for the study of lung cancer, and association for molecular pathology. J Thorac Oncol. 8:823–859. 2013. View Article : Google Scholar : PubMed/NCBI
5	Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
6	Vidal J, Clavé S, de Muga S, González I, Pijuan L, Gimeno J, Remón J, Reguart N, Viñolas N, Gironés R, et al: Assessment of ALK status by FISH on 1,000 Spanish non-small cell lung cancer patients. J Thorac Oncol. 9:1816–1820. 2014. View Article : Google Scholar : PubMed/NCBI
7	Alì G, Proietti A, Pelliccioni S, Niccoli C, Lupi C, Sensi E, Giannini R, Borrelli N, Menghi M, Chella A, et al: ALK rearrangement in a large series of consecutive non-small cell lung cancers: Comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment. Arch Pathol Lab Med. 138:1449–1458. 2014. View Article : Google Scholar : PubMed/NCBI
8	Cabillic F, Gros A, Dugay F, Begueret H, Mesturoux L, Chiforeanu DC, Dufrenot L, Jauffret V, Dachary D, Corre R, et al: Parallel FISH and immunohistochemical studies of ALK status in 3,244 non-small-cell lung cancers reveal major discordances. J Thorac Oncol. 9:295–306. 2014. View Article : Google Scholar : PubMed/NCBI
9	Zhao F, Xu M, Lei H, Zhou Z, Wang L, Li P, Zhao J and Hu P: Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: A meta-analysis. PLoS One. 10:e01173332015. View Article : Google Scholar : PubMed/NCBI
10	Ou SH, Klempner SJ, Greenbowe JR, Azada M, Schrock AB, Ali SM, Ross JS, Stephens PJ and Miller VA: Identification of a novel HIP1-ALK fusion variant in non-small-cell lung cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib. J Thorac Oncol. 9:1821–1825. 2014. View Article : Google Scholar : PubMed/NCBI
11	Iyevleva AG, Raskin GA, Tiurin VI, Sokolenko AP, Mitiushkina NV, Aleksakhina SN, Garifullina AR, Strelkova TN, Merkulov VO, Ivantsov AO, et al: Novel ALK fusion partners in lung cancer. Cancer Lett. 362:116–121. 2015. View Article : Google Scholar : PubMed/NCBI
12	Conde E, Suárez-Gauthier A, Benito A, Garrido P, García-Campelo R, Biscuola M, Paz-Ares L, Hardisson D, de Castro J, Camacho MC, et al: Accurate identification of ALK positive lung carcinoma patients: Novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry. PLoS One. 9:e1072002014. View Article : Google Scholar : PubMed/NCBI
13	Wang Q, Yang X, He Y, Ma Q, Lin L, Fu P and Xiao H: Droplet digital PCR for absolute quantification of EML4-ALK gene rearrangement in lung adenocarcinoma. J Mol Diagn. 17:515–520. 2015. View Article : Google Scholar : PubMed/NCBI
14	Mancikova V, Cruz R, Inglada-Pérez L, Fernández-Rozadilla C, Landa I, Cameselle-Teijeiro J, Celeiro C, Pastor S, Velázquez A, Marcos R, et al: Thyroid cancer GWAS identifies 10q26.12 and 6q14.1 as novel susceptibility loci and reveals genetic heterogeneity among populations. Int J Cancer. 137:1870–1878. 2015. View Article : Google Scholar : PubMed/NCBI
15	Bozzetti C, Nizzoli R, Tiseo M, Squadrilli A, Lagrasta C, Buti S, Gasparro D, Zanoni D, Majori M, De Filippo M, et al: ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients. Diagn Cytopathol. 43:941–946. 2015. View Article : Google Scholar : PubMed/NCBI
16	Proietti A, Alì G, Pelliccioni S, Lupi C, Sensi E, Boldrini L, Servadio A, Chella A, Ribechini A, Cappuzzo F, et al: Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: Comparison with histological assessment. Cancer Cytopathol. 122:445–1453. 2014. View Article : Google Scholar : PubMed/NCBI